About Protein ANKUB1
Protein ANKUB1 (ANKUB1) is a protein
from Homo sapiens identified by UniProt accession
A6NFN9, 502 residues long.
MolForge cross-references it against 0 known binders and
15 disease associations.
Target properties
| Protein name | Protein ANKUB1 |
| UniProt accession | A6NFN9 |
| Gene | ANKUB1 |
| Organism | Homo sapiens |
| Length | 502 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (15)
Diseases linked to this target (Open Targets).
- pulse pressure measurement · score 0.29
- smoking status measurement · score 0.28
- substance abuse · score 0.24
- antisocial behaviour measurement · score 0.24
- attention deficit hyperactivity disorder · score 0.24
- diet measurement · score 0.19
- myocardial infarction · score 0.19
- electrocardiography · score 0.04
- sex hormone-binding globulin measurement · score 0.04
- central nervous system cancer · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NFN9-F1 | alphafold | PREDICTED | 74.37 | — |
Amino-acid sequence (502 residues)
MRIFIAFEGS FEPFDVSADE TVEVVKLMIK DYFHIPLSED KQGRRYLELM YAGAALKDSW SLADVGISFC STLKCFVKEE DKPTLYVFNA VTQDTMPVME SISLLDKTVS DLRTLVTLRC GLPVSVYCLR TPRGLEMYDC NTLKDYQTDI GTTLRLDVWD GWKEFLMGCL LGQKLKVQRY LSKEGPVLKY QKRVALYIAA FCGYIELTEW ALKQGARPHE AVGVHPYRAW CHEALHADVS KCPIHAAAEA GQLLILKAFV NYSVLCLECK NAAGQTPLTI VFKHKHKDCV LYLLSKMWST VSFPKISVPM RIYIKIKQWI LRAQSHSLHK SQFCGARVFG AKVGDTVMVD GFTKPKMTSK SWHKAGNSDS QSIVLKLPSL SKQTASSKPV NPLAISQPDT RKQALKFHPL VNASSFSELQ KHQQQNQKKI TATARKKEKL IKNTYLPQVP LPPVSRVGYS HPSFFYATPS ADFLLKSSFS SFLEHSGKTP WENAIYCLAV AR
Explore Protein ANKUB1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets